Highlights of This Issue 2193

SPECIAL FEATURES

CCR 20th Anniversary Commentary

2195  CCR 20th Anniversary Commentary: Expanding the Epigenetic Therapeutic Portfolio
       Susan E. Bates, Robert W. Robey, and Richard L. Piekaz

2198  CCR 20th Anniversary Commentary: Vorinostat—Gateway to Epigenetic Therapy
       Wm. Kevin Kelly, Paul Marks, and Victoria M. Richon

CCR Translations

2201  A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2
       Yanping Xiao and Gordon J. Freeman
       See related article, p. 2359

2204  Diffuse Large B-cell Lymphoma Classification Tied Up Nicely with a "String"
       Lisa M. Rimsza
       See related article, p. 2367

Molecular Pathways

2207  Molecular Pathways: GLI1-Induced Drug Glucuronidation in Resistant Cancer Cells
       Hiba Ahmad Zahreddine and Katherine L.B. Borden

CCR Focus

2212  Quit Early, Quit Often
       Susan E. Bates

2213  Lung Cancer in the Era of Precision Medicine
       Katerina Politi and Roy S. Herbst

2221  EGFR: The Paradigm of an Oncogene-Driven Lung Cancer
       Gregory J. Riely and Helena A. Yu

2227  Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine
       Ryohi Katayama, Christine M. Lovly, and Alice T. Shaw

2236  Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics
       David R. Gandara, Peter S. Hammerman, Martin L. Sos, Primo N. Lara Jr, and Fred R. Hirsch

2244  Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?
       M. Catherine Pietanza, Lauren Averett Byer, John D. Minna, and Charles M. Rudin

2256  Immune Checkpoint Modulation for Non–Small Cell Lung Cancer
       Jean-Charles Soria, Aurélien Marabelle, Julie R. Brahmer, and Scott Gettinger

Special Report

2263  Accelerating the Delivery of Patient-Centered, High-Quality Cancer Care
       Edward Abrahams, Margaret Foti, and Marcia A. Kean

CANCER THERAPY: CLINICAL

2268  Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer

2278  Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation
Martijn P. Lolkema, Hilde H. Bohets, Hendrik-Tobias Arkenau, Ann Lambo, Erio Barale, Maja J.A. de Jonge, Leni van Doorn, Peter Hellemans, Johann S. de Bono, and Ferry A.L.M. Eskens

Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial
Lawrence G. Lum, Archana Thakur, Zaid Al-Kadhimi, Gerald A. Colvin, Francis J. Cummings, Robert D. Legare, Don S. Dixon, Nicola Kouttab, Abby Maizel, William Colaiace, Qin Liu, and Ritesh Rathore

Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer

Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms
Michele Cioffi, Sara Trabulo, Manuel Hidalgo, Eithne Costello, William Greenhalf, Mert Ekeran, Joerg Kleeff, Bruno Sainz Jr, and Christopher Heeschen

Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation
Masanori Hasegawa, Raj Kumar Sinha, Manoj Kumar, Maroof Alam, Li Yin, Deepak Raina, Akriti Kharbanda, Govind Panchamoorthy, Dikshi Gupta, Harpal Singh, Surender Kharbanda, and Donald Kufe

Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL
Matthew C. Stubbs, Wonil Kim, Megan Bariteau, Tina Davis, Siddhar Vempati, Janna Minehart, Matthew Witkin, Jun Qi, Andrei V. Krivtsov, James E. Bradner, Andrew L. Kung, and Scott A. Armstrong

Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein
Murali Janakiram, Jordan M. Chinai, Susan Fineberg, Andras Fiser, Cristina Montagna, Ramadevi Madavarapu, Ekaterina Castano, Hyungjun Jeon, Kim C. Ohaegbulam, Ruihua Zhao, Aimin Zhao, Steven C. Almo, Joseph A. Sparano, and Xingxing Zang

Molecular Changes Associated with Acquired Resistance to Crizotinib in ROSI-Rearranged Non–Small Cell Lung Cancer
Ahnah Song, Tae Min Kim, Dong-Wan Kim, Soyeon Kim, Bhumsuk Keam, Se-Hoon Lee, and Dae Seog Heo

Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects

miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma
Yijun Yang, Fei Li, Manujendra N. Saha, Jahangir Abdi, Lugui Qiu, and Hong Chang

Correction: Ceritinib for the Treatment of Late-Stage (Metastatic) Non–Small Cell Lung Cancer

Correction: Ceritinib for the Treatment of Late-Stage (Metastatic) Non–Small Cell Lung Cancer

CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org
For more information please visit www.aacrjournals.org
ABOUT THE COVER

The cover shows a section of a bone marrow biopsy from a patient with acute myeloid leukemia (AML). Immunohistochemical staining shows Desert Hedgehog positive osteoblasts underlining the hypothesis of paracrine Hedgehog pathway activation in AML cells. For details, see the article by Wellbrock and colleagues on page 2388 of this issue.